Satellos Bioscience Inc. (TSE:MSCL) has released an update.
Satellos Bioscience Inc. reports unanimous shareholder approval for all director nominees and the adoption of key resolutions, including a reverse stock split, a new Equity Incentive Plan, and amendments to the company’s bylaws during its recent Annual and Special Meeting. The company, focused on developing treatments for muscle diseases, has a lead drug candidate for Duchenne muscular dystrophy and a proprietary discovery platform aimed at enhancing muscle repair and regeneration.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
